Bill brings 30 years of experience in healthcare as a former practicing physician, serial medtech entrepreneur and chief executive. He previously was CEO of Correvio (CORV:NASDAQ) where he oversaw the development of its own direct sales force in Europe, acquiring of a company with a complementary product (AGGRASTAT), assembling of an international distribution network, in-licensing three additional products and increasing valuation by over five-fold. Prior to that, he was Founder/CEO of Angiotech (ANPI:NASDAQ), a world leader in the emerging field of drug-loaded medical devices and implants and achieved a market capitalization of greater than $2 billion.
He is an innovator and inventor with over 200 patents and patent applications, including the discovery and development of Persona IQ, the TAXUS® Drug-Eluting Coronary Stent, the Ranger® drug eluting balloon, the Zilver PTX Peripheral Drug-Eluting Stent and the Quill barbed wound closure device. He has overseen the development of products used in over 50 million patients, generating revenues of over $25 billion.
Bill holds a Doctorate of Medicine from University of British Columbia, a Master of Science from University of British Columbia and a Bachelor of Science from McGill University.